Molecular mechanisms driving oncogenesis in KRAS mutant non-small cell lung cancer

被引：0
|
作者：
Holderfield, Matthew
McCormick, Frank
Nagel, Tobi
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-5752
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5752
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A pooled shRNA screen for erlotinib sensitizers in Kras-mutant non-small cell lung cancer
    Cordes, Shaun
    Dompe, Nick
    Lee, James
    Li, Li
    Rivers, Celina
    Tang, Zhijun
    Luk, Wilman
    Bennett, Greg
    Shames, David
    Modrusan, Zora
    Davis, David P.
    [J]. CANCER RESEARCH, 2010, 70
  • [32] Combined inhibition of MDM2 and MEK for KRAS mutant non-small cell lung cancer
    Hata, Aaron N.
    Archibald, Hannah L.
    Gomez-Caraballo, Maria D.
    DeBussche, Laurent R.
    Sidhu, Sukhvinder
    Watters, James
    Engelman, Jeffrey A.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [33] KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
    Rosell, Rafael
    Codony-Servat, Jordi
    Gonzalez, Jessica
    Santarpia, Mariacarmela
    Jain, Anisha
    Shivamallu, Chandan
    Wang, Yu
    Gimenez-Capitan, Ana
    Molina-Vila, Miguel A.
    Nilsson, Jonas
    Gonzalez-Cao, Maria
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 195
  • [34] SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
    Xiaowen Wang
    Hong Zhang
    Russell Sapio
    Jun Yang
    Justin Wong
    Xin Zhang
    Jessie Y. Guo
    Sharon Pine
    Holly Van Remmen
    Hong Li
    Eileen White
    Chen Liu
    Megerditch Kiledjian
    Dimitri G. Pestov
    X. F. Steven Zheng
    [J]. Nature Communications, 12
  • [35] Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Jeanson, Arnaud
    Tomasini, Pascale
    Souquet-Bressand, Maxime
    Brandone, Nicolas
    Boucekine, Mohamed
    Grangeon, Mathieu
    Chaleat, Solene
    Khobta, Natalyia
    Milia, Julie
    Mhanna, Laurent
    Greillier, Laurent
    Biemar, Julie
    Nanni, Isabelle
    Ouafik, L'houcine
    Garcia, Stephane
    Mazieres, Julien
    Barlesi, Fabrice
    Mascaux, Celine
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1095 - 1101
  • [36] Treatment of KRAS-Mutant Non-Small Cell Lung Cancer The End of the Beginning for Targeted Therapies
    Kaufman, Jacob
    Stinchcombe, Thomas E.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (18): : 1835 - 1837
  • [37] AKT and gefitinib resistance in mutant KRAS non-small cell lung cancers through mechanisms dependent of acetylation
    Jeannot, V.
    Busser, B.
    Brambilla, E.
    Wislez, M.
    Robin, B.
    Cadranel, J.
    Coll, J. L.
    Hurbin, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S119 - S119
  • [38] SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
    Wang, Xiaowen
    Zhang, Hong
    Sapio, Russell
    Yang, Jun
    Wong, Justin
    Zhang, Xin
    Guo, Jessie Y.
    Pine, Sharon
    Van Remmen, Holly
    Li, Hong
    White, Eileen
    Liu, Chen
    Kiledjian, Megerditch
    Pestov, Dimitri G.
    Zheng, X. F. Steven
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [39] Molecular mechanisms of non-small cell lung cancer growth and drug resistance
    Alam, S. K. Kayum
    Astone, Matteo
    Liu, Ping
    Wang, Li
    Coyle, Abbygail M.
    Dankert, Erin N.
    Hoffman, Dane K.
    Hall, Stephanie R.
    Zhang, Wei
    Kuang, Rui
    Roden, Anja C.
    Mansfield, Aaron S.
    Hoeppner, Luke H.
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [40] Chromatin modification driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer
    Li, Chendi
    Qin, Qian
    Syed, Mohammed Usman
    Nimbalkar, Anahita
    Karakyriakou, Barbara
    Clark, Sarah E.
    Saiki, Anne Y.
    Hughes, Paul E.
    Ott, Chris
    Pinello, Luca
    Hata, Aaron N.
    [J]. CANCER RESEARCH, 2023, 83 (07)
12345